ILMN vs PPCB · rev $4.34B vs P/E 0.0, $3.9M cap
Illumina Inc (ILMN) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Illumina Inc (ILMN) is a diagnostics & research company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported ILMN revenue for 2025-12-28 was $4.34B. Net income was $850.0M. Revenue was down 0.7% from 2024-12-29 to 2025-12-28. ILMN currently screens at market cap $15.84B.
PPCB does not have a complete income-statement cache yet.
ILMN currently screens at market cap $15.84B. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the ILMN and PPCB stock pages for the full models.
Not investment advice.